Clinical management of hereditary colorectal cancer syndromes

Current Opinion in Gastroenterology

Volumn 20, Issue 1, 2004, Pages 32-42

  Half, Elizabeth E ^a   Bresalier, Robert S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Familial adenomatous polyposis; Hereditary nonpolyposis colorectal cancer; Juvenile polyposis syndrome; Peutz Jeghers syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC;

ADENOMATOUS POLYP; CANCER GENETICS; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; DNA SEQUENCE; FAMILIAL CANCER; FAMILIAL POLYPOSIS; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; HEALTH CARE COST; HUMAN; JUVENILE POLYP; LINKAGE ANALYSIS; MUTATIONAL ANALYSIS; NONHUMAN; PEUTZ JEGHERS SYNDROME; REVIEW;

EID: 4344577385     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200401000-00008     Document Type: Review

References (53)

1. Young RC: Cancer statistics, 2002: progress or cause for concern? CA Cancer J Clin 2002, 52:6-7.
2. Boardman LA: Heritable colorectal cancer syndromes: recognition and preventive management. Gastroenterol Clin North Am 2002, 31:1107-1131.
3. Petersen GM, Slack J, Nakamura Y: Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 1991, 100:1658-1664.
4. Offerhaus GJ, Giardiello FM, Krusn AJ, et al.: The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992, 102:1980-1982.
5. Abraham SC, Nobukawa B, Giardiello FM, et al.: Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol 2000, 157:747-754.
6. Lyons LA, Lewis RA, Strong LC, et al.: A genetic study of Gardner syndrome and congenital hypertrophy of the retinal pigment epithelium. Am J Hum Genet 1988, 42:290-296.
7. Shields JA, Shields CL, Eagle RC Jr, et al.: Adenocarcinoma arising from congenital hypertrophy of retinal pigment epithelium. Arch Ophthalmol 2001, 119:597-602.
8. Young J, Barker M, Robertson T, et al.: A case of myoepithelial carcinoma displaying biallelic inactivation of the tumour suppressor gene APC in a patient with familial adenomatous polyposis. J Clin Pathol 2002, 55:230-231.
9. Grady WM: Genetic testing for high-risk colon cancer patients. Gastroenterology 2003, 124:1574-1594.
10. Sieber OM, Lipton L, Crabtree M, et al.: Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003, 348:791-799.
11. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology 2001, 121:195-197.
12. Maire F, Hammel P, Terris B, et al.: Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis. Gut 2002, 51:446-449.
13. Healy JC, Reznek RH, Clark SK, et al.: MR appearances of desmoid tumors in familial adenomatous polyposis. AJR Am J Roentgenol 1997, 169:465-472.
14. Bulow C, Vasen H, Jarvinen H, et al.: Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. Gastroenterology 2000, 119:1454-1460.
15. Parc YR, Olschwang S, Desaint B, et al.: Familial adenomatous polyposis: prevalence of adenomas in the ileal pouch after restorative proctocolectomy. Ann Surg 2001, 233:360-364.
16. Farnell MB, Sakorafas GH, Sarr MG, et al.: Villous tumors of the duodenum: reappraisal of local vs. extended resection. J Gastrointest Surg 2000, 4:13-21, discussion 22-23.
17. Chung RS, Church JM, vanStolk R: Pancreas-sparing duodenectomy: indications, surgical technique, and results. Surgery 1995, 117:254-259.
18. Kalady MF, Clary BM, Tyler DS, et al.: Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis. J Gastrointest Surg 2002, 6:82-87.
19. Cruz-Correa M, Hylind LM, Romans KE, et al.: Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002, 122:641-645.
20. Giardiello FM, Hamilton SR, Krush AJ, et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328:1313-1316.
21. Steinbach G, Lynch PM, Phillips RK, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946-1952.
22. Giardiello FM, Yang VW, Hylind LM, et al.: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002, 346:1054-1059.
23. Lynch HT, de la Chapelle A: Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999, 36:801-818.
24. Strand M, Prolla TA, Liskay RM, et al.: Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. Nature 1993, 365:274-276.
25. Chung DC, Rustgi AK: DNA mismatch repair and cancer. Gastroenterology 1995, 109:1685-1699.
26. Peltomaki P, Aaltonen LA, Sistonen P, et al.: Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993, 260:810-812.
27. Wu Y, Berends MJ, Post JG, et al.: Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology 2001, 120:1580-1587.
28. Marra G, Boland CR: Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995, 87:1114-1125.
29. Dunlop MG, Farrington SM, Carothers AD, et al.: Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997, 6:105-110.
30. Lothe RA, Peltomaki P, Meling GI, et al.: Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993, 53:5849-5852.
31. Vasen HF, Nagengast FM, Khan PM: Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 1995, 345:1183-1184.
32. Jarvinen HJ, Mecklin JP, Sistonen P: Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995, 108:1405-1411.
33. de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al.: Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002, 45:1588-1594.
34. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. 2003;1.
35. Lynch HT: Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? Dis Colon Rectum 1996, 39:109-110.
36. Church JM: Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer. Ann Med 1996, 28:479-482.
37. Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, et al.: Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 1998, 58:5473-5477.
38. Sinicrope FA, Lemoine M, Xi L, et al.: Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 1999, 117:350-358.
39. Jass JR, Williams CB, Bussey HJ, et al.: Juvenile polyposis - a precancerous condition. Histopathology 1988, 13:619-630.
40. Howe JR, Mitros FA, Summers RW: The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998, 5:751-756.
41. Desai DC, Murday V, Phillips RK, et al.: A survey of phenotypic features in juvenile polyposis. J Med Genet 1998, 35:476-481.
42. Giardiello FM, Hamilton SR, Kern SE, et al.: Colorectal neoplasia in juvenile polyposis or juvenile polyps. Arch Dis Child 1991, 66:971-975.
43. Sayed MG, Ahmed AF, Ringold JR, et al.: Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann Surg Oncol 2002, 9:901-906.
44. Solomon CH, Pho LN, Burt RW: Current status of genetic testing for colorectal cancer susceptibility. Oncology (Huntingt) 2002, 16:161-171, discussion 176, 179-180.
45. Woodford-Richens K, Sevan S, Churchman M, et al.: Analysis of genetic and phenotypic heterogeneity in juvenile polyposis. Gut 2000, 46:656-660.
46. Friedl W, Uhlhaas S, Schulmann K, et al.: Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers. Hum Genet 2002, 111:108-111.
47. Tovar JA, Eizaguirre I, Albert A, et al.: Peutz-Jeghers syndrome in children: report of two cases and review of the literature. J Pediatr Surg 1983, 18:1-6.
48. Giardiello FM, Brensinger JD, Tersmette AC, et al.: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000, 119:1447-1453.
49. Jenne DE, Reimann H, Nezu J, et al.: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998, 18:38-43.
50. Mehenni H, Gehrig C, Nezu J, et al.: Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 1998, 63:1641-1650.
51. Dunlop MG: Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 2002, 51(suppl 5):V21-V27.
52. Winawer SJ, Fletcher RH, Miller L, et al.: Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997, 112:594-642.
53. De Leng WW, Westerman AM, Weterman MA, et al.: Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. Clin Cancer Res 2003, 9:3065-3072.